

# APPROPRIATE AND VALUE-BASED CARE CONFERENCE 2025

Maximising Value for All

16-17 OCTOBER 2025



## Impact of a pharmacist-run dupilumab monitoring service

Xiaoling HUANG<sup>1</sup>, Germaine CHUA<sup>2</sup>, Ruki WIJESINGHE<sup>1</sup>, Yik Weng YEOW<sup>1</sup>

<sup>1</sup>National Skin Centre, <sup>2</sup>National Healthcare Group Polyclinics


### Introduction


- Dupilumab is an effective and well-tolerated biologic for moderate-severe atopic dermatitis (AD).
- Common adverse reactions in Asian population: ocular symptoms, head and neck dermatitis
- The Pharmacist Eczema Clinic (PEC) implemented a dupilumab monitoring service to review patients for potential adverse reactions 2 to 4 weeks after initiation of dupilumab.

### Aim

- To evaluate the clinical outcomes, patient satisfaction, and cost savings of a pharmacist-led dupilumab monitoring service.

### Methods

 A retrospective chart review was conducted at the National Skin Centre on the patients who were started on dupilumab between 31 July 2020 - 4 Jan 2023.

 Outcomes of those reviewed by PEC were compared with those seen by dermatologist

Primary outcomes:

- Number of drug-related problems (DRPs) addressed
- 28-day dermatology-related walk-in rates.

Secondary outcomes:

- Patient satisfaction
- Cost-savings to patient

### Results

 Sample: 72 patients (36 patients per group), baseline demographics comparable



**DRPs addressed:**

- Dermatologist 4 vs PEC 5

	DRPs		
	Adverse drug event	Drug-drug interaction	Untreated indication
Dermatologist	2	0	2
PEC	1	2	2



**28-day dermatology-related walk-ins:**

- Dermatologist 3 vs PEC 0
- The 3 walk-ins were due to AD flare.



**Patient satisfaction: 22/23 PEC patients (96.5%) rated care as *very good* or *excellent***



**Cost:**

- PEC manpower cost/patient: SGD 13.93
- Average PEC consultation fee (after subsidy): SGD 19.94
- **Average direct cost savings for patients reviewed by PEC vs dermatologist: SGD 14.92 (42.8% reduction in consultation fees)**

### Conclusion

The pharmacist-run dupilumab monitoring service demonstrated satisfactory clinical outcome and high patient satisfaction at a lower cost to patients.